ReportWire

Tag: Medical

  • Early prenatal care, considered best for moms and babies, is on the decline in the US, data shows

    [ad_1]

    Early prenatal care improves the chances of having a healthy pregnancy and baby. But a new federal report shows it’s been on the decline.The share of U.S. births to women who began prenatal care in the first trimester dropped from 78.3% in 2021 to 75.5% in 2024, according to data released by the Centers for Disease Control and Prevention on Thursday.Meanwhile, starting care later in pregnancy or getting no care at all has been on the rise. Prenatal care beginning in the second trimester rose from 15.4% to 17.3%, and starting care in the third trimester or getting no care went from 6.3% to 7.3%.“We know that early engagement in prenatal care is linked to better overall health outcomes,” said Dr. Clayton Alfonso, an OB-GYN at Duke University in North Carolina. When patients delay medical care during pregnancy, “we’ve missed that window to optimize both fetal and maternal care.”While the trend identified in the report held for nearly all racial and ethnic groups, the decrease in early prenatal care was higher for moms in minority groups. For example, first-trimester care dropped from 69.7% in 2021 to 65.1% in 2024 for Black mothers. Getting late or no prenatal care raises the risk of maternal mortality, which is much higher among Black mothers.Michelle Osterman, lead author of the report, said the overall findings represent a shift. Between 2016 and 2021, the timing of when U.S. women started prenatal care had been improving.The earlier prenatal visits begin, doctors said, the earlier problems can be caught. Visits give doctors a chance to share health guidance, and can include blood pressure checks, screenings, blood tests, physical exams and ultrasound scans.The report doesn’t provide reasons why prenatal care is starting later. But the proliferation of maternity care deserts across the nation is a growing concern, said Dr. Grace Ferguson, an OB-GYN in Pittsburgh.Many hospitals have shut down labor and delivery units “and the prenatal care providers that work at those hospitals also have probably moved,” said Ferguson, who was not involved with the report.A 2024 March of Dimes report found that more than 35% of U.S. counties are maternity care deserts, meaning there’s no birthing facility or obstetric provider. Women living in these areas receive less prenatal care, the report showed.Ferguson, who provides abortions as part of her OB-GYN care, said post-Roe v. Wade abortion restrictions may play a part because some obstetricians are choosing not to practice in states with more restrictive laws.Alfonso, who was not involved in the CDC report, said he also suspects that access issues for patients are pushing prenatal care later, particularly in rural areas. Patients may have to travel farther to get to appointments and may struggle to find a practice that accepts their insurance, particularly if they have Medicaid.Doctors fear that things could get worse.“If this trend continues,” Alfonso said, “I worry about kind of what that would mean for morbidity and mortality for our moms.”

    Early prenatal care improves the chances of having a healthy pregnancy and baby. But a new federal report shows it’s been on the decline.

    The share of U.S. births to women who began prenatal care in the first trimester dropped from 78.3% in 2021 to 75.5% in 2024, according to data released by the Centers for Disease Control and Prevention on Thursday.

    Meanwhile, starting care later in pregnancy or getting no care at all has been on the rise. Prenatal care beginning in the second trimester rose from 15.4% to 17.3%, and starting care in the third trimester or getting no care went from 6.3% to 7.3%.

    “We know that early engagement in prenatal care is linked to better overall health outcomes,” said Dr. Clayton Alfonso, an OB-GYN at Duke University in North Carolina. When patients delay medical care during pregnancy, “we’ve missed that window to optimize both fetal and maternal care.”

    While the trend identified in the report held for nearly all racial and ethnic groups, the decrease in early prenatal care was higher for moms in minority groups. For example, first-trimester care dropped from 69.7% in 2021 to 65.1% in 2024 for Black mothers. Getting late or no prenatal care raises the risk of maternal mortality, which is much higher among Black mothers.

    Michelle Osterman, lead author of the report, said the overall findings represent a shift. Between 2016 and 2021, the timing of when U.S. women started prenatal care had been improving.

    The earlier prenatal visits begin, doctors said, the earlier problems can be caught. Visits give doctors a chance to share health guidance, and can include blood pressure checks, screenings, blood tests, physical exams and ultrasound scans.

    The report doesn’t provide reasons why prenatal care is starting later. But the proliferation of maternity care deserts across the nation is a growing concern, said Dr. Grace Ferguson, an OB-GYN in Pittsburgh.

    Many hospitals have shut down labor and delivery units “and the prenatal care providers that work at those hospitals also have probably moved,” said Ferguson, who was not involved with the report.

    A 2024 March of Dimes report found that more than 35% of U.S. counties are maternity care deserts, meaning there’s no birthing facility or obstetric provider. Women living in these areas receive less prenatal care, the report showed.

    Ferguson, who provides abortions as part of her OB-GYN care, said post-Roe v. Wade abortion restrictions may play a part because some obstetricians are choosing not to practice in states with more restrictive laws.

    Alfonso, who was not involved in the CDC report, said he also suspects that access issues for patients are pushing prenatal care later, particularly in rural areas. Patients may have to travel farther to get to appointments and may struggle to find a practice that accepts their insurance, particularly if they have Medicaid.

    Doctors fear that things could get worse.

    “If this trend continues,” Alfonso said, “I worry about kind of what that would mean for morbidity and mortality for our moms.”

    [ad_2]

    Source link

  • Cidel Asset Management Inc. Grows Stock Position in Eli Lilly and Company $LLY

    [ad_1]

    Cidel Asset Management Inc. raised its position in Eli Lilly and Company (NYSE:LLYFree Report) by 26.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 26,726 shares of the company’s stock after acquiring an additional 5,591 shares during the period. Eli Lilly and Company makes up about 1.2% of Cidel Asset Management Inc.’s holdings, making the stock its 27th largest holding. Cidel Asset Management Inc.’s holdings in Eli Lilly and Company were worth $20,392,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

    Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Sumitomo Mitsui Financial Group Inc. purchased a new stake in Eli Lilly and Company during the second quarter valued at about $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $29,000. Steph & Co. boosted its holdings in Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $31,000. Finally, Bare Financial Services Inc grew its stake in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

    Key Headlines Impacting Eli Lilly and Company

    Here are the key news stories impacting Eli Lilly and Company this week:

    Analyst Upgrades and Downgrades

    Several equities research analysts have issued reports on LLY shares. Leerink Partners increased their target price on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a research report on Thursday, February 5th. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Zacks Research cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, Morgan Stanley upped their target price on shares of Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,218.88.

    Get Our Latest Stock Report on LLY

    Eli Lilly and Company Stock Up 0.2%

    LLY stock opened at $1,040.12 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The stock has a market cap of $983.31 billion, a price-to-earnings ratio of 45.32, a price-to-earnings-growth ratio of 1.21 and a beta of 0.39. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company’s 50 day moving average is $1,052.39 and its 200 day moving average is $907.31.

    Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

    Eli Lilly and Company Increases Dividend

    The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 26.14%.

    Eli Lilly and Company Profile

    (Free Report)

    Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

    Featured Stories

    Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

    Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)



    Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • How Lindsey Vonn can compete with a ruptured ACL

    [ad_1]

    Lindsey Vonn wiped out in a downhill race on Jan. 30. She got up limping, then was airlifted from the course. The diagnosis: a ruptured ACL — a season-ending injury for most.But the three-time Olympic medalist announced on Tuesday she would go on to compete in her fifth Games.On Friday, she completed her downhill training run without issue at the Tofane Alpine Skiing Centre ahead of Sunday’s medal event in Cortina d’Ampezzo.Video above: U.S. Skiers talk about Lindsey Vonn competing in Italy Olympics despite torn ACLFor anyone who’s hobbled off the field, it’s hard not to ask: How?“It is a big deal to tear your ACL,” said Lindsey Lepley, an associate professor of athletic training at the University of Michigan. “And doing anything while being ACL-deficient is a big deal.”Vonn, 41, who is set to be the oldest Alpine skier to race at a Winter Olympics, has an extensive history of knee injuries and surgeries, including two prior ACL injuries. Dr. Martin Roche, a surgeon at the Hospital for Special Surgery, says Vonn’s first injuries date back to the beginning of her professional career in the 2000s.She’s had problems with both knees, but her left was the “stronger” one, according to Roche, who performed a partial knee replacement on the Olympian’s right knee in 2024. After Friday’s crash, her left knee is now injured — a new turn in Vonn’s long injury saga.What is the ACL and why is it important?The ACL — also known as the anterior cruciate ligament — is a ligament that connects the bones of the knee, stabilizing the joint and preventing one bone from sliding in front of the other.“The knee is not a joint that is completely stable,” Dr. Anthony Petrosini, an orthopedic surgeon at Hackensack Meridian Health, said. “The ligaments play a great role in keeping the knee in position.”Petrosini, who has torn his own ACL, says the structure is easily injured because it has a hefty responsibility in controlling the knee’s rotational stability. It’s the most common knee injury, affecting more than 200,000 people per year in the United States.Weight-bearing and high-speed activities, particularly those involving sudden twists and stops, place the greatest burden on the ACL.And skiing fits that bill. It’s among the highest-risk sports for ACL injuries. Vonn’s sex and prior injuries further increase that risk.When injured, the ACL can be partially torn, also known as a tear, or fully separated, referred to as a rupture. The terms are frequently used interchangeably, as Vonn did on Tuesday.What happens when the ACL is injured?A jolt of pain is felt when the ACL is first injured. Some people also feel a pop or instability in the knee. Fluid then accumulates in the joint, causing swelling and stiffness. The inflammatory response can also cause a locking sensation and reduced range of motion.For many, that means trouble standing on the injured knee and continued pain.The structures above the knee also feel the pain. Lepley studies how muscles of the upper leg shut down after a knee injury — a process called muscle inhibition.“It’s sort of this unique forgetfulness that happens between the brain and the muscle,” Lepley said.The injury also travels up to the brain, triggering a fear response. “People are going to have fear of re‑injury,” Lepley explained, noting the psychological component can cause someone to change movement patterns.That’s why, Lepley says, Vonn was likely performing box jumps after the injury. “They’re sort of testing that fear,” Lepley said, noting the exercises can also help fight off muscle inhibition. “If you can’t jump and stabilize yourself on solid ground, that’s a good indication that somebody has too much hesitation.”In a video posted on Instagram on Thursday, a day before her completed training run, Vonn squats with weights, lunges from side to side and does fast kicks against a ball.How to treat an injured ACLOnce the ACL is torn, it doesn’t regenerate in the same way that bone does. “Unfortunately, we’re not like lizards,” Lepley said.Most people undergo surgery to reconstruct the ligament, and nearly all athletes get the procedure after the injury, according to Roche.While a surgical approach doesn’t speed up recovery time, it can stabilize the knee, reduce the risk of further injury and allow for return to high-demanding activities like skiing. Some data suggests surgery can also reduce the risk of osteoarthritis — a common long-term concern after ACL injury — though the evidence is conflicting.Regardless of whether someone has surgery, months of rehab are standard. Those who don’t opt for surgery stick to pain control and rehab, learning to live without a functioning ACL.Vonn said on Tuesday that surgery “hasn’t been discussed.”“It’s not really on my radar screen right now. The Olympics are the only thing that I’m thinking about,” she said. “We’re doing everything to make sure I am making smart and safe decisions.”Has anyone ever skied on an injured ACL?Yes, some of Vonn’s teammates said they’ve done it. Other skiers, like Slovakian Veronika Velez-Zuzulová have done it, too. And Vonn says she’s done it before.“It’s possible,” Roche said. But other parts of the leg need to compensate.“When that ligament is gone, your muscles have to step up to help stabilize the joint,” Lepley said.All the experts CNN spoke with emphasized that an immediate return to competition is far from the norm — and not recommended. Far more often, athletes do the opposite. Hitting the slopes would expose Vonn to substantial risk of further injury.Plus, there was more to her injury. She also reported bone bruising and meniscal damage, both common companions to ACL injuries. These additional injuries raise the risk further, making her return to racing even more dangerous. The good news, though, is that Vonn didn’t report any significant bone fractures, Roche said.Roche, who knows Vonn’s medical history well, says it comes down to the athlete.“She knows her body better than anyone,” Roche said. “She’ll be able to determine if she can overcome any injury to her knee quickly or if it’s going to set her back.”What to watch for when Vonn returns for fresh powderVonn is set to begin racing on Sunday.“I don’t think she’s going to be able to perform at 100%,” Lepley said. “But I think she’s going to be able to make the best of a bad situation.”Parts of the course that put more stress on one knee could be especially risky. Lepley says the Olympian might lack symmetry as she compensates.The biggest concern is Vonn’s meniscus, which acts as a shock absorber and helps the knee move smoothly. Without a functioning ACL, the structure is more vulnerable and, if injured, it’s notoriously difficult to heal.At the finish line, three things will matter most, Lepley says: a medical exam to check for any additional damage, close monitoring of pain and swelling and a renewed focus on restoring normal motion and walking. And if her knees are on her side, a medal.“She’s in good hands,” Petrosini said. “To be able to pull off what she’s attempting is really remarkable.”

    Lindsey Vonn wiped out in a downhill race on Jan. 30. She got up limping, then was airlifted from the course. The diagnosis: a ruptured ACL — a season-ending injury for most.

    But the three-time Olympic medalist announced on Tuesday she would go on to compete in her fifth Games.

    On Friday, she completed her downhill training run without issue at the Tofane Alpine Skiing Centre ahead of Sunday’s medal event in Cortina d’Ampezzo.

    Video above: U.S. Skiers talk about Lindsey Vonn competing in Italy Olympics despite torn ACL

    For anyone who’s hobbled off the field, it’s hard not to ask: How?

    “It is a big deal to tear your ACL,” said Lindsey Lepley, an associate professor of athletic training at the University of Michigan. “And doing anything while being ACL-deficient is a big deal.”

    Vonn, 41, who is set to be the oldest Alpine skier to race at a Winter Olympics, has an extensive history of knee injuries and surgeries, including two prior ACL injuries. Dr. Martin Roche, a surgeon at the Hospital for Special Surgery, says Vonn’s first injuries date back to the beginning of her professional career in the 2000s.

    She’s had problems with both knees, but her left was the “stronger” one, according to Roche, who performed a partial knee replacement on the Olympian’s right knee in 2024. After Friday’s crash, her left knee is now injured — a new turn in Vonn’s long injury saga.

    What is the ACL and why is it important?

    The ACL — also known as the anterior cruciate ligament — is a ligament that connects the bones of the knee, stabilizing the joint and preventing one bone from sliding in front of the other.

    “The knee is not a joint that is completely stable,” Dr. Anthony Petrosini, an orthopedic surgeon at Hackensack Meridian Health, said. “The ligaments play a great role in keeping the knee in position.”

    Petrosini, who has torn his own ACL, says the structure is easily injured because it has a hefty responsibility in controlling the knee’s rotational stability. It’s the most common knee injury, affecting more than 200,000 people per year in the United States.

    Weight-bearing and high-speed activities, particularly those involving sudden twists and stops, place the greatest burden on the ACL.

    And skiing fits that bill. It’s among the highest-risk sports for ACL injuries. Vonn’s sex and prior injuries further increase that risk.

    When injured, the ACL can be partially torn, also known as a tear, or fully separated, referred to as a rupture. The terms are frequently used interchangeably, as Vonn did on Tuesday.

    What happens when the ACL is injured?

    A jolt of pain is felt when the ACL is first injured. Some people also feel a pop or instability in the knee. Fluid then accumulates in the joint, causing swelling and stiffness. The inflammatory response can also cause a locking sensation and reduced range of motion.

    For many, that means trouble standing on the injured knee and continued pain.

    The structures above the knee also feel the pain. Lepley studies how muscles of the upper leg shut down after a knee injury — a process called muscle inhibition.

    “It’s sort of this unique forgetfulness that happens between the brain and the muscle,” Lepley said.

    The injury also travels up to the brain, triggering a fear response. “People are going to have fear of re‑injury,” Lepley explained, noting the psychological component can cause someone to change movement patterns.

    That’s why, Lepley says, Vonn was likely performing box jumps after the injury. “They’re sort of testing that fear,” Lepley said, noting the exercises can also help fight off muscle inhibition. “If you can’t jump and stabilize yourself on solid ground, that’s a good indication that somebody has too much hesitation.”

    In a video posted on Instagram on Thursday, a day before her completed training run, Vonn squats with weights, lunges from side to side and does fast kicks against a ball.

    How to treat an injured ACL

    Once the ACL is torn, it doesn’t regenerate in the same way that bone does. “Unfortunately, we’re not like lizards,” Lepley said.

    Most people undergo surgery to reconstruct the ligament, and nearly all athletes get the procedure after the injury, according to Roche.

    While a surgical approach doesn’t speed up recovery time, it can stabilize the knee, reduce the risk of further injury and allow for return to high-demanding activities like skiing. Some data suggests surgery can also reduce the risk of osteoarthritis — a common long-term concern after ACL injury — though the evidence is conflicting.

    Regardless of whether someone has surgery, months of rehab are standard. Those who don’t opt for surgery stick to pain control and rehab, learning to live without a functioning ACL.

    Vonn said on Tuesday that surgery “hasn’t been discussed.”

    “It’s not really on my radar screen right now. The Olympics are the only thing that I’m thinking about,” she said. “We’re doing everything to make sure I am making smart and safe decisions.”

    Has anyone ever skied on an injured ACL?

    Yes, some of Vonn’s teammates said they’ve done it. Other skiers, like Slovakian Veronika Velez-Zuzulová have done it, too. And Vonn says she’s done it before.

    “It’s possible,” Roche said. But other parts of the leg need to compensate.

    “When that ligament is gone, your muscles have to step up to help stabilize the joint,” Lepley said.

    All the experts CNN spoke with emphasized that an immediate return to competition is far from the norm — and not recommended. Far more often, athletes do the opposite. Hitting the slopes would expose Vonn to substantial risk of further injury.

    Plus, there was more to her injury. She also reported bone bruising and meniscal damage, both common companions to ACL injuries. These additional injuries raise the risk further, making her return to racing even more dangerous. The good news, though, is that Vonn didn’t report any significant bone fractures, Roche said.

    Roche, who knows Vonn’s medical history well, says it comes down to the athlete.

    “She knows her body better than anyone,” Roche said. “She’ll be able to determine if she can overcome any injury to her knee quickly or if it’s going to set her back.”

    What to watch for when Vonn returns for fresh powder

    Vonn is set to begin racing on Sunday.

    “I don’t think she’s going to be able to perform at 100%,” Lepley said. “But I think she’s going to be able to make the best of a bad situation.”

    Parts of the course that put more stress on one knee could be especially risky. Lepley says the Olympian might lack symmetry as she compensates.

    The biggest concern is Vonn’s meniscus, which acts as a shock absorber and helps the knee move smoothly. Without a functioning ACL, the structure is more vulnerable and, if injured, it’s notoriously difficult to heal.

    At the finish line, three things will matter most, Lepley says: a medical exam to check for any additional damage, close monitoring of pain and swelling and a renewed focus on restoring normal motion and walking. And if her knees are on her side, a medal.

    “She’s in good hands,” Petrosini said. “To be able to pull off what she’s attempting is really remarkable.”

    [ad_2]

    Source link

  • Head to Head Review: CERo Therapeutics (NASDAQ:CERO) & Sandoz Group (OTCMKTS:SDZNY)

    [ad_1]

    Sandoz Group (OTCMKTS:SDZNYGet Free Report) and CERo Therapeutics (NASDAQ:CEROGet Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

    Insider & Institutional Ownership

    0.1% of Sandoz Group shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

    Analyst Ratings

    This is a summary of recent ratings and target prices for Sandoz Group and CERo Therapeutics, as reported by MarketBeat.

    Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
    Sandoz Group 0 1 0 1 3.00
    CERo Therapeutics 1 3 0 0 1.75

    CERo Therapeutics has a consensus price target of $45.00, indicating a potential upside of 92,683.51%. Given CERo Therapeutics’ higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Sandoz Group.

    Profitability

    This table compares Sandoz Group and CERo Therapeutics’ net margins, return on equity and return on assets.

    Net Margins Return on Equity Return on Assets
    Sandoz Group N/A N/A N/A
    CERo Therapeutics N/A N/A -209.40%

    Volatility and Risk

    Sandoz Group has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.

    Earnings & Valuation

    This table compares Sandoz Group and CERo Therapeutics”s top-line revenue, earnings per share and valuation.

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
    Sandoz Group $10.36 billion 3.31 $1.00 million N/A N/A
    CERo Therapeutics N/A N/A -$8.30 million ($102.61) 0.00

    Sandoz Group has higher revenue and earnings than CERo Therapeutics.

    Summary

    Sandoz Group beats CERo Therapeutics on 6 of the 9 factors compared between the two stocks.

    About Sandoz Group

    (Get Free Report)

    Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

    About CERo Therapeutics

    (Get Free Report)

    CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.



    Receive News & Ratings for Sandoz Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sandoz Group and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Effects Of Lifetime Use Of Alcohol And Cannabis

    [ad_1]

    A closer look at the effects of lifetime use of alcohol and cannabis as science rethinks moderation and health outcomes.

    As social norms around drinking and cannabis continue to shift, researchers are taking a closer look at how these substances affect health over a lifetime. While liquor companies are struggling as Gen Z and younger millennials move away from cannabis, what are the long term effects of lifetime use of alcohol and cannabis? While alcohol has long been treated as a cultural staple, cannabis is increasingly being studied not just for short-term effects, but for how moderate use over decades may influence brain health, cognition, and overall risk.

    RELATED: Why Anxiety Feels Worse Than Ever

    A recently published study examining lifetime cannabis use offers a perspective challenging many assumptions. Researchers found adults with a history of cannabis use performed as well as, and in some cases better than, non-users on tests measuring attention, memory, and processing speed. The study also identified larger brain volume in regions associated with learning and memory among some cannabis users, particularly in older adults. Importantly, the findings focused on lifetime exposure rather than heavy or daily use, suggesting moderate consumption may not carry the cognitive risks once broadly assumed.

    Earlier research linking cannabis to memory and attention problems often centered on heavy use, frequent intoxication, or adolescent exposure. Lifetime studies paint a more nuanced picture, indicating use patterns matter significantly. Occasional or moderate cannabis use appears to differ sharply from chronic, high-dose consumption when it comes to long-term cognitive outcomes.

    Alcohol research has moved in a different direction. For years, moderate drinking was commonly associated with potential cardiovascular benefits, particularly red wine consumption. More recent analyses, however, have cast doubt on those claims. Large population studies and updated public health guidance now suggest even moderate alcohol use increases lifetime cancer risk and may contribute to cognitive decline and dementia.

    Alcohol is a known neurotoxin, and long-term exposure has been linked to reduced brain volume and structural changes in areas related to memory and executive function. While some individuals may experience short-term cardiovascular benefits from low-level drinking, those effects are increasingly outweighed by evidence of cumulative harm over time.

    RELATED: Is CBD Next On The Fed’s Hit List

    At the population level, alcohol also carries a heavier social and medical burden. Alcohol use disorder affects more people than cannabis use disorder, and alcohol is a contributing factor in liver disease, accidents, and premature death. Cannabis dependence exists, but fatal overdose does not, and the overall risk profile differs substantially.

    None of this suggests cannabis is risk-free or appropriate for everyone. Individual health conditions, mental health history, age of initiation, and frequency of use all matter. But as research on lifetime exposure expands, the gap between long-held assumptions and current evidence is narrowing.

    For readers trying to make informed choices, the emerging consensus is clear: moderation, context, and long-term patterns matter more than outdated narratives. As science continues to evolve, so too does the understanding of how alcohol and cannabis shape health across a lifetime.

    [ad_2]

    Amy Hansen

    Source link

  • Quest Diagnostics Incorporated (NYSE:DGX) Given Average Rating of “Moderate Buy” by Analysts

    [ad_1]

    Quest Diagnostics Incorporated (NYSE:DGXGet Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen brokerages that are covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $198.2667.

    A number of analysts have commented on DGX shares. Weiss Ratings restated a “buy (b-)” rating on shares of Quest Diagnostics in a research note on Monday, December 29th. Evercore ISI lifted their target price on shares of Quest Diagnostics from $185.00 to $190.00 and gave the stock an “in-line” rating in a research report on Wednesday, October 8th. UBS Group lifted their target price on Quest Diagnostics from $180.00 to $190.00 and gave the stock a “neutral” rating in a research note on Friday, October 17th. Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Finally, Barclays upgraded Quest Diagnostics from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research note on Friday.

    View Our Latest Stock Report on DGX

    Insider Activity

    In other news, SVP Mark E. Delaney sold 7,946 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $187.35, for a total value of $1,488,683.10. Following the sale, the senior vice president directly owned 7,530 shares of the company’s stock, valued at approximately $1,410,745.50. This represents a 51.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Vicky B. Gregg sold 1,250 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $191.76, for a total transaction of $239,700.00. Following the completion of the transaction, the director directly owned 17,037 shares of the company’s stock, valued at approximately $3,267,015.12. The trade was a 6.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 64,289 shares of company stock worth $12,318,360 over the last ninety days. Company insiders own 8.16% of the company’s stock.

    Institutional Trading of Quest Diagnostics

    A number of hedge funds have recently made changes to their positions in DGX. Brighton Jones LLC bought a new stake in Quest Diagnostics during the fourth quarter worth about $323,000. Janney Montgomery Scott LLC lifted its position in shares of Quest Diagnostics by 11.8% in the 2nd quarter. Janney Montgomery Scott LLC now owns 20,142 shares of the medical research company’s stock worth $3,618,000 after purchasing an additional 2,132 shares during the period. PFG Investments LLC lifted its holdings in Quest Diagnostics by 4.9% in the second quarter. PFG Investments LLC now owns 1,952 shares of the medical research company’s stock worth $351,000 after buying an additional 92 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Quest Diagnostics by 5.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,407 shares of the medical research company’s stock valued at $2,768,000 after purchasing an additional 830 shares during the period. Finally, Ameritas Advisory Services LLC purchased a new position in Quest Diagnostics during the second quarter valued at $35,000. 88.06% of the stock is owned by institutional investors.

    Quest Diagnostics Stock Performance

    Shares of Quest Diagnostics stock opened at $186.90 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.13 and a quick ratio of 1.04. Quest Diagnostics has a one year low of $157.20 and a one year high of $197.55. The business has a 50-day simple moving average of $181.36 and a 200 day simple moving average of $180.73. The firm has a market capitalization of $20.79 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 2.37 and a beta of 0.66.

    Quest Diagnostics Announces Dividend

    The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 28th. Investors of record on Tuesday, January 13th were paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Tuesday, January 13th. Quest Diagnostics’s payout ratio is presently 37.56%.

    Quest Diagnostics Company Profile

    (Get Free Report)

    Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

    Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

    Featured Stories

    Analyst Recommendations for Quest Diagnostics (NYSE:DGX)



    Receive News & Ratings for Quest Diagnostics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Quest Diagnostics and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Core Alternative Capital Lowers Stake in Eli Lilly and Company $LLY

    [ad_1]

    Core Alternative Capital trimmed its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 10.0% in the third quarter, HoldingsChannel.com reports. The fund owned 11,920 shares of the company’s stock after selling 1,318 shares during the quarter. Eli Lilly and Company comprises about 2.6% of Core Alternative Capital’s investment portfolio, making the stock its 5th biggest position. Core Alternative Capital’s holdings in Eli Lilly and Company were worth $9,095,000 at the end of the most recent quarter.

    A number of other hedge funds also recently modified their holdings of LLY. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after buying an additional 1,183,038 shares during the period. Laurel Wealth Advisors LLC boosted its position in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares in the last quarter. Norges Bank bought a new position in Eli Lilly and Company in the second quarter valued at approximately $8,827,714,000. Jennison Associates LLC raised its position in Eli Lilly and Company by 4.3% during the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after purchasing an additional 226,620 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Eli Lilly and Company by 2.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after purchasing an additional 103,119 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

    Analyst Ratings Changes

    Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Truist Financial lifted their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research report on Wednesday, November 19th. UBS Group assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, January 6th. They issued a “buy” rating and a $1,250.00 target price for the company. HSBC reaffirmed a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Finally, National Bankshares set a $1,286.00 price objective on shares of Eli Lilly and Company in a research note on Monday, December 1st. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Buy” and a consensus target price of $1,173.91.

    Read Our Latest Stock Report on LLY

    Eli Lilly and Company Stock Performance

    Shares of Eli Lilly and Company stock opened at $1,038.23 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock has a market cap of $981.52 billion, a price-to-earnings ratio of 50.79, a P/E/G ratio of 0.80 and a beta of 0.35. The company’s fifty day moving average is $1,058.15 and its 200 day moving average is $885.09.

    Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the company earned $1.18 EPS. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

    Eli Lilly and Company Increases Dividend

    The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

    Key Headlines Impacting Eli Lilly and Company

    Here are the key news stories impacting Eli Lilly and Company this week:

    Eli Lilly and Company Profile

    (Free Report)

    Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

    Read More

    Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

    Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)



    Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • UnitedHealth Group Incorporated $UNH Shares Bought by CapWealth Advisors LLC

    [ad_1]

    CapWealth Advisors LLC increased its position in shares of UnitedHealth Group Incorporated (NYSE:UNHFree Report) by 5,415.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 45,615 shares of the healthcare conglomerate’s stock after buying an additional 44,788 shares during the period. CapWealth Advisors LLC’s holdings in UnitedHealth Group were worth $15,751,000 at the end of the most recent reporting period.

    Other large investors also recently modified their holdings of the company. Norges Bank acquired a new position in shares of UnitedHealth Group during the second quarter worth $3,837,207,000. Berkshire Hathaway Inc acquired a new position in shares of UnitedHealth Group during the 2nd quarter worth about $1,572,193,000. Dodge & Cox raised its position in shares of UnitedHealth Group by 117.7% during the 2nd quarter. Dodge & Cox now owns 8,750,560 shares of the healthcare conglomerate’s stock worth $2,729,912,000 after acquiring an additional 4,730,192 shares in the last quarter. Lone Pine Capital LLC acquired a new position in UnitedHealth Group in the second quarter valued at approximately $528,273,000. Finally, Amundi raised its holdings in UnitedHealth Group by 33.8% during the second quarter. Amundi now owns 6,191,871 shares of the healthcare conglomerate’s stock worth $1,904,372,000 after purchasing an additional 1,565,245 shares in the last quarter. 87.86% of the stock is owned by hedge funds and other institutional investors.

    UnitedHealth Group Stock Up 2.7%

    Shares of NYSE:UNH opened at $347.70 on Thursday. The company has a market cap of $314.96 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 2.04 and a beta of 0.42. UnitedHealth Group Incorporated has a fifty-two week low of $234.60 and a fifty-two week high of $606.36. The firm’s 50-day simple moving average is $330.93 and its 200-day simple moving average is $322.74. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 0.71.

    UnitedHealth Group (NYSE:UNHGet Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The healthcare conglomerate reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.87 by $0.05. The company had revenue of $113.16 billion for the quarter, compared to analyst estimates of $113.19 billion. UnitedHealth Group had a return on equity of 19.23% and a net margin of 4.04%.The firm’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $7.15 EPS. As a group, equities research analysts predict that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current year.

    UnitedHealth Group Dividend Announcement

    The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 16th. Shareholders of record on Monday, December 8th were issued a $2.21 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $8.84 dividend on an annualized basis and a yield of 2.5%. UnitedHealth Group’s dividend payout ratio (DPR) is 46.14%.

    Analyst Ratings Changes

    UNH has been the topic of a number of recent analyst reports. Zacks Research raised shares of UnitedHealth Group from a “strong sell” rating to a “hold” rating in a research report on Monday, October 6th. Royal Bank Of Canada raised their price objective on UnitedHealth Group from $286.00 to $408.00 and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Sanford C. Bernstein upped their target price on UnitedHealth Group from $433.00 to $440.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Leerink Partners set a $410.00 price objective on UnitedHealth Group and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Finally, The Goldman Sachs Group initiated coverage on shares of UnitedHealth Group in a research report on Tuesday, October 14th. They set a “buy” rating and a $406.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $385.75.

    Read Our Latest Research Report on UNH

    UnitedHealth Group News Summary

    Here are the key news stories impacting UnitedHealth Group this week:

    About UnitedHealth Group

    (Free Report)

    UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

    UnitedHealthcare is the company’s benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.

    Featured Articles

    Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNHFree Report).

    Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)



    Receive News & Ratings for UnitedHealth Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for UnitedHealth Group and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • UnitedHealth Group Incorporated $UNH Stock Holdings Lowered by First National Advisers LLC

    [ad_1]

    First National Advisers LLC trimmed its position in shares of UnitedHealth Group Incorporated (NYSE:UNHFree Report) by 44.7% in the third quarter, HoldingsChannel reports. The firm owned 2,142 shares of the healthcare conglomerate’s stock after selling 1,730 shares during the period. First National Advisers LLC’s holdings in UnitedHealth Group were worth $740,000 as of its most recent filing with the Securities & Exchange Commission.

    Other institutional investors and hedge funds have also added to or reduced their stakes in the company. North Capital Inc. boosted its position in UnitedHealth Group by 16.2% during the 3rd quarter. North Capital Inc. now owns 194 shares of the healthcare conglomerate’s stock worth $67,000 after acquiring an additional 27 shares during the period. Sunflower Bank N.A. lifted its holdings in UnitedHealth Group by 1.5% in the third quarter. Sunflower Bank N.A. now owns 1,916 shares of the healthcare conglomerate’s stock worth $662,000 after purchasing an additional 28 shares during the period. Axis Wealth Partners LLC increased its stake in UnitedHealth Group by 1.7% during the 3rd quarter. Axis Wealth Partners LLC now owns 1,631 shares of the healthcare conglomerate’s stock valued at $563,000 after buying an additional 28 shares during the period. Abound Wealth Management lifted its stake in shares of UnitedHealth Group by 13.5% in the 3rd quarter. Abound Wealth Management now owns 244 shares of the healthcare conglomerate’s stock worth $84,000 after acquiring an additional 29 shares during the period. Finally, Seamount Financial Group Inc. increased its stake in shares of UnitedHealth Group by 4.7% during the second quarter. Seamount Financial Group Inc. now owns 818 shares of the healthcare conglomerate’s stock valued at $255,000 after acquiring an additional 37 shares during the period. 87.86% of the stock is owned by institutional investors.

    Analyst Ratings Changes

    Several equities analysts have recently issued reports on the company. Weiss Ratings upgraded UnitedHealth Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, October 24th. The Goldman Sachs Group began coverage on UnitedHealth Group in a report on Tuesday, October 14th. They set a “buy” rating and a $406.00 target price on the stock. Wells Fargo & Company lifted their price objective on shares of UnitedHealth Group from $267.00 to $400.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 7th. Bank of America increased their target price on shares of UnitedHealth Group from $350.00 to $390.00 and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Finally, Leerink Partners set a $410.00 price target on UnitedHealth Group and gave the company an “outperform” rating in a report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, UnitedHealth Group presently has an average rating of “Moderate Buy” and an average target price of $385.75.

    Get Our Latest Report on UNH

    Key Headlines Impacting UnitedHealth Group

    Here are the key news stories impacting UnitedHealth Group this week:

    UnitedHealth Group Stock Performance

    Shares of UNH stock opened at $331.25 on Friday. The stock’s fifty day simple moving average is $330.33 and its 200-day simple moving average is $322.09. The company has a market capitalization of $300.06 billion, a price-to-earnings ratio of 17.29, a P/E/G ratio of 2.00 and a beta of 0.42. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 0.71. UnitedHealth Group Incorporated has a 1-year low of $234.60 and a 1-year high of $606.36.

    UnitedHealth Group (NYSE:UNHGet Free Report) last released its earnings results on Tuesday, October 28th. The healthcare conglomerate reported $2.92 earnings per share for the quarter, beating the consensus estimate of $2.87 by $0.05. The company had revenue of $113.16 billion for the quarter, compared to analysts’ expectations of $113.19 billion. UnitedHealth Group had a return on equity of 19.23% and a net margin of 4.04%.The business’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $7.15 EPS. On average, sell-side analysts predict that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current fiscal year.

    UnitedHealth Group Dividend Announcement

    The business also recently declared a quarterly dividend, which was paid on Tuesday, December 16th. Stockholders of record on Monday, December 8th were paid a $2.21 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $8.84 dividend on an annualized basis and a dividend yield of 2.7%. UnitedHealth Group’s dividend payout ratio is 46.14%.

    UnitedHealth Group Company Profile

    (Free Report)

    UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

    UnitedHealthcare is the company’s benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.

    Further Reading

    Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNHFree Report).

    Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)



    Receive News & Ratings for UnitedHealth Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for UnitedHealth Group and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Aloka the Peace Dog reunites with Walk for Peace following surgery

    [ad_1]

    Aloka the Peace Dog was reunited with the Walk for Peace monks for the first time since undergoing leg surgery following an injury during the 2,300-mile Walk for Peace in early January. The reunion happened in Charlotte, North Carolina, where Aloka briefly appeared in front of supporters during the group’s lunch stop. He appeared to be in good spirits. The monks say his spirits remain high and he is healing well. “We are happy to share that Aloka is recovering very well from his surgery,” the group wrote on a Facebook post after his surgery.Video below: More about the Walk for Peace and the monks’ stop in North CarolinaA team at the Charleston Veterinary Referral Center in Charleston, South Carolina, performed the surgery and assisted Aloka through the early stages of his recovery.The monks say Aloka received a professional therapy massage and red-light therapy. He will not be walking with the group for now so he can continue healing.Find a map of the monks’ path on sister statin WXII’s website.

    Aloka the Peace Dog was reunited with the Walk for Peace monks for the first time since undergoing leg surgery following an injury during the 2,300-mile Walk for Peace in early January.

    The reunion happened in Charlotte, North Carolina, where Aloka briefly appeared in front of supporters during the group’s lunch stop. He appeared to be in good spirits.

    The monks say his spirits remain high and he is healing well. “We are happy to share that Aloka is recovering very well from his surgery,” the group wrote on a Facebook post after his surgery.

    Video below: More about the Walk for Peace and the monks’ stop in North Carolina

    A team at the Charleston Veterinary Referral Center in Charleston, South Carolina, performed the surgery and assisted Aloka through the early stages of his recovery.

    The monks say Aloka received a professional therapy massage and red-light therapy. He will not be walking with the group for now so he can continue healing.

    Find a map of the monks’ path on sister statin WXII’s website.

    [ad_2]

    Source link

  • Oak Family Advisors LLC Makes New $1.98 Million Investment in Eli Lilly and Company $LLY

    [ad_1]

    Oak Family Advisors LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,594 shares of the company’s stock, valued at approximately $1,979,000.

    Other hedge funds have also recently modified their holdings of the company. Laurel Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $8,827,714,000. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after buying an additional 765,010 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in Eli Lilly and Company by 13.4% during the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock valued at $3,715,913,000 after buying an additional 564,736 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

    Analyst Upgrades and Downgrades

    A number of research analysts have weighed in on LLY shares. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Zacks Research raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 1st. Daiwa Capital Markets set a $1,230.00 price target on Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Daiwa America raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 16th. Finally, Leerink Partners set a $1,234.00 target price on Eli Lilly and Company in a research note on Monday, January 5th. Five analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $1,169.00.

    View Our Latest Analysis on Eli Lilly and Company

    Trending Headlines about Eli Lilly and Company

    Here are the key news stories impacting Eli Lilly and Company this week:

    Eli Lilly and Company Price Performance

    NYSE:LLY opened at $1,063.90 on Friday. The stock has a 50 day moving average of $1,037.16 and a two-hundred day moving average of $861.18. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The firm has a market cap of $1.01 trillion, a P/E ratio of 52.05, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

    Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the company posted $1.18 earnings per share. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

    Eli Lilly and Company Increases Dividend

    The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is presently 33.86%.

    About Eli Lilly and Company

    (Free Report)

    Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

    Further Reading

    Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)



    Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Merck & Co., Inc. $MRK Shares Acquired by First Pacific Financial

    [ad_1]

    First Pacific Financial raised its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 14.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 47,555 shares of the company’s stock after purchasing an additional 6,082 shares during the quarter. First Pacific Financial’s holdings in Merck & Co., Inc. were worth $3,991,000 at the end of the most recent reporting period.

    A number of other institutional investors and hedge funds also recently modified their holdings of MRK. Legend Financial Advisors Inc. purchased a new stake in shares of Merck & Co., Inc. during the second quarter valued at $25,000. Darwin Wealth Management LLC raised its holdings in Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after buying an additional 216 shares during the period. Kilter Group LLC acquired a new stake in Merck & Co., Inc. during the 2nd quarter worth about $27,000. Bare Financial Services Inc lifted its stake in Merck & Co., Inc. by 51.9% during the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after buying an additional 125 shares in the last quarter. Finally, Evolution Wealth Management Inc. purchased a new stake in Merck & Co., Inc. during the second quarter valued at about $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

    Insider Buying and Selling at Merck & Co., Inc.

    In other news, EVP David Michael Williams sold 8,614 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $83.59, for a total transaction of $720,044.26. Following the completion of the sale, the executive vice president owned 24,578 shares in the company, valued at approximately $2,054,475.02. This represents a 25.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is owned by corporate insiders.

    Merck & Co., Inc. Price Performance

    MRK opened at $105.20 on Friday. The stock has a fifty day moving average price of $96.98 and a 200 day moving average price of $87.76. The company has a current ratio of 1.66, a quick ratio of 1.44 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $107.59. The stock has a market cap of $261.11 billion, a price-to-earnings ratio of 13.90, a PEG ratio of 1.00 and a beta of 0.29.

    Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Friday, January 30th. The company reported $1.94 earnings per share for the quarter. Merck & Co., Inc. had a net margin of 29.63% and a return on equity of 44.54%. Analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

    Merck & Co., Inc. Increases Dividend

    The business also recently declared a quarterly dividend, which will be paid on Thursday, January 8th. Shareholders of record on Monday, December 15th will be given a $0.85 dividend. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.81. This represents a $3.40 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Monday, December 15th. Merck & Co., Inc.’s payout ratio is presently 44.91%.

    Analyst Ratings Changes

    Several research analysts have recently weighed in on the stock. Bank of America lifted their target price on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. The Goldman Sachs Group raised their price objective on shares of Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a report on Monday. Citigroup started coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price for the company. Finally, Morgan Stanley lifted their price target on Merck & Co., Inc. from $100.00 to $102.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Hold” and a consensus target price of $110.13.

    Read Our Latest Stock Report on Merck & Co., Inc.

    Merck & Co., Inc. Profile

    (Free Report)

    Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

    Founded in the late 19th century as the U.S.

    See Also

    Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

    Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)



    Receive News & Ratings for Merck & Co. Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Co. Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • UnitedHealth Group Incorporated $UNH Stock Holdings Lifted by Carnegie Investment Counsel

    [ad_1]

    Carnegie Investment Counsel lifted its stake in shares of UnitedHealth Group Incorporated (NYSE:UNHFree Report) by 2.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,621 shares of the healthcare conglomerate’s stock after acquiring an additional 2,316 shares during the quarter. Carnegie Investment Counsel’s holdings in UnitedHealth Group were worth $36,471,000 at the end of the most recent reporting period.

    A number of other large investors have also made changes to their positions in the company. Bayforest Capital Ltd boosted its holdings in shares of UnitedHealth Group by 685.7% during the first quarter. Bayforest Capital Ltd now owns 55 shares of the healthcare conglomerate’s stock worth $29,000 after purchasing an additional 48 shares during the period. LFA Lugano Financial Advisors SA acquired a new stake in UnitedHealth Group during the second quarter valued at $25,000. Sagard Holdings Management Inc. acquired a new position in UnitedHealth Group in the 2nd quarter worth about $29,000. Islay Capital Management LLC acquired a new stake in shares of UnitedHealth Group during the 2nd quarter valued at about $31,000. Finally, Nova Wealth Management Inc. lifted its stake in UnitedHealth Group by 339.1% in the first quarter. Nova Wealth Management Inc. now owns 101 shares of the healthcare conglomerate’s stock valued at $53,000 after acquiring an additional 78 shares during the last quarter. Institutional investors and hedge funds own 87.86% of the company’s stock.

    UnitedHealth Group Trading Up 1.3%

    UNH stock opened at $331.76 on Friday. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 0.71. The firm has a market cap of $300.52 billion, a P/E ratio of 17.32, a P/E/G ratio of 2.13 and a beta of 0.43. UnitedHealth Group Incorporated has a 1-year low of $234.60 and a 1-year high of $606.36. The business’s 50 day moving average is $333.71 and its 200-day moving average is $318.99.

    UnitedHealth Group (NYSE:UNHGet Free Report) last released its quarterly earnings results on Tuesday, October 28th. The healthcare conglomerate reported $2.92 EPS for the quarter, topping analysts’ consensus estimates of $2.87 by $0.05. UnitedHealth Group had a return on equity of 19.23% and a net margin of 4.04%.The business had revenue of $113.16 billion for the quarter, compared to analyst estimates of $113.19 billion. During the same period in the prior year, the company earned $7.15 EPS. UnitedHealth Group’s revenue for the quarter was up 12.2% on a year-over-year basis. Equities analysts anticipate that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current fiscal year.

    UnitedHealth Group Dividend Announcement

    The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 16th. Stockholders of record on Monday, December 8th were paid a $2.21 dividend. This represents a $8.84 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, December 8th. UnitedHealth Group’s dividend payout ratio (DPR) is 46.14%.

    Analyst Ratings Changes

    Several equities analysts have commented on the stock. Barclays increased their target price on shares of UnitedHealth Group from $352.00 to $386.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Deutsche Bank Aktiengesellschaft downgraded UnitedHealth Group from a “buy” rating to a “hold” rating and set a $333.00 price target on the stock. in a report on Wednesday, October 29th. Mizuho upped their price objective on shares of UnitedHealth Group from $300.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, October 9th. Piper Sandler lowered their price target on UnitedHealth Group from $423.00 to $417.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 28th. Finally, Morgan Stanley increased their target price on UnitedHealth Group from $325.00 to $395.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Seventeen research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $385.54.

    View Our Latest Analysis on UNH

    UnitedHealth Group Profile

    (Free Report)

    UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

    UnitedHealthcare is the company’s benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.

    Featured Articles

    Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNHFree Report).

    Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)



    Receive News & Ratings for UnitedHealth Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for UnitedHealth Group and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Rowan Chapman Sells 4,366 Shares of Natera (NASDAQ:NTRA) Stock

    [ad_1]

    Natera, Inc. (NASDAQ:NTRAGet Free Report) Director Rowan Chapman sold 4,366 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $243.10, for a total value of $1,061,374.60. Following the transaction, the director directly owned 5,777 shares in the company, valued at approximately $1,404,388.70. This trade represents a 43.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

    Natera Stock Performance

    Shares of Natera stock opened at $233.13 on Thursday. The stock has a market capitalization of $32.25 billion, a PE ratio of -101.80 and a beta of 1.63. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $246.90. The stock has a 50 day moving average price of $204.00 and a two-hundred day moving average price of $175.57.

    Natera (NASDAQ:NTRAGet Free Report) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same quarter in the prior year, the business earned ($0.26) earnings per share. Natera’s revenue for the quarter was up 34.7% on a year-over-year basis. Research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

    Hedge Funds Weigh In On Natera

    A number of hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. boosted its position in Natera by 42.5% in the first quarter. PNC Financial Services Group Inc. now owns 4,206 shares of the medical research company’s stock worth $595,000 after purchasing an additional 1,255 shares during the last quarter. ASR Vermogensbeheer N.V. bought a new stake in shares of Natera during the 1st quarter worth $243,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Natera by 4.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 905,676 shares of the medical research company’s stock worth $128,072,000 after buying an additional 38,180 shares during the last quarter. Deutsche Bank AG grew its position in Natera by 185.8% during the first quarter. Deutsche Bank AG now owns 246,482 shares of the medical research company’s stock valued at $34,855,000 after buying an additional 160,243 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Natera by 224.7% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 141,641 shares of the medical research company’s stock valued at $20,029,000 after buying an additional 98,015 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

    Analyst Upgrades and Downgrades

    NTRA has been the subject of a number of analyst reports. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. BNP Paribas Exane upgraded Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price target for the company in a research note on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. BNP Paribas upgraded Natera to a “hold” rating and set a $172.00 target price on the stock in a report on Monday, October 27th. Finally, Barclays lifted their target price on Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Fifteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $225.29.

    Check Out Our Latest Stock Analysis on NTRA

    About Natera

    (Get Free Report)

    Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

    See Also

    Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)



    Receive News & Ratings for Natera Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Natera and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Ceredex Value Advisors LLC Has $49.26 Million Stock Position in Danaher Corporation $DHR

    [ad_1]

    Ceredex Value Advisors LLC lifted its stake in shares of Danaher Corporation (NYSE:DHRFree Report) by 1.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 249,377 shares of the conglomerate’s stock after purchasing an additional 3,862 shares during the quarter. Danaher comprises 1.1% of Ceredex Value Advisors LLC’s investment portfolio, making the stock its 17th biggest holding. Ceredex Value Advisors LLC’s holdings in Danaher were worth $49,262,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

    Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. MGO One Seven LLC raised its holdings in shares of Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock worth $5,145,000 after acquiring an additional 20,813 shares during the last quarter. Chicago Capital LLC increased its holdings in Danaher by 11.6% during the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after purchasing an additional 1,391 shares in the last quarter. Weitz Investment Management Inc. increased its holdings in Danaher by 6.1% during the 2nd quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock worth $104,094,000 after purchasing an additional 30,300 shares in the last quarter. UniSuper Management Pty Ltd raised its stake in shares of Danaher by 1.6% in the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock worth $34,954,000 after purchasing an additional 2,667 shares during the last quarter. Finally, Nvwm LLC lifted its holdings in shares of Danaher by 20.4% in the second quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock valued at $1,401,000 after purchasing an additional 1,204 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

    Wall Street Analysts Forecast Growth

    DHR has been the subject of several recent research reports. Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 price target (down previously from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Wells Fargo & Company reiterated a “positive” rating on shares of Danaher in a report on Thursday, October 23rd. Robert W. Baird set a $247.00 price target on shares of Danaher in a report on Wednesday, October 22nd. Finally, Barclays increased their price objective on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $243.39.

    Read Our Latest Analysis on Danaher

    Danaher Stock Performance

    NYSE DHR opened at $228.41 on Friday. The company has a market capitalization of $161.33 billion, a PE ratio of 47.09, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The company has a 50-day simple moving average of $211.54 and a 200 day simple moving average of $202.99.

    Danaher (NYSE:DHRGet Free Report) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the previous year, the company earned $1.71 earnings per share. The company’s quarterly revenue was up 4.4% on a year-over-year basis. On average, research analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

    Danaher Dividend Announcement

    The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio is 26.39%.

    Insiders Place Their Bets

    In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. This represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 30,248 shares of company stock valued at $6,609,663 over the last ninety days. 11.10% of the stock is currently owned by insiders.

    About Danaher

    (Free Report)

    Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

    Further Reading

    Institutional Ownership by Quarter for Danaher (NYSE:DHR)



    Receive News & Ratings for Danaher Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Danaher and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Artisan Partners Limited Partnership Sells 24,514 Shares of Medtronic PLC $MDT

    [ad_1]

    Artisan Partners Limited Partnership lowered its holdings in shares of Medtronic PLC (NYSE:MDTFree Report) by 2.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,203,236 shares of the medical technology company’s stock after selling 24,514 shares during the quarter. Artisan Partners Limited Partnership’s holdings in Medtronic were worth $104,886,000 at the end of the most recent quarter.

    Several other institutional investors and hedge funds have also modified their holdings of the business. 1248 Management LLC acquired a new stake in Medtronic during the 1st quarter worth approximately $26,000. Twin Tree Management LP acquired a new position in shares of Medtronic in the first quarter valued at approximately $29,000. Activest Wealth Management increased its position in shares of Medtronic by 3,577.8% during the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after acquiring an additional 322 shares in the last quarter. Investment Management Corp VA ADV raised its holdings in shares of Medtronic by 144.2% during the first quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock worth $36,000 after acquiring an additional 238 shares during the period. Finally, GFG Capital LLC bought a new stake in Medtronic in the 2nd quarter valued at $36,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

    Insider Transactions at Medtronic

    In related news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William R. Jellison bought 2,500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was bought at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the transaction, the director directly owned 5,000 shares of the company’s stock, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.26% of the stock is currently owned by corporate insiders.

    Analysts Set New Price Targets

    MDT has been the topic of several recent research reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Wednesday, October 8th. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 target price on shares of Medtronic in a research report on Wednesday. Citigroup boosted their target price on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Daiwa Capital Markets raised their price target on shares of Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Finally, Robert W. Baird lifted their price objective on shares of Medtronic from $103.00 to $109.00 and gave the company a “neutral” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and an average price target of $108.50.

    View Our Latest Report on Medtronic

    Medtronic Stock Down 0.7%

    NYSE MDT opened at $100.12 on Thursday. The business has a fifty day moving average price of $94.80 and a two-hundred day moving average price of $90.70. The stock has a market capitalization of $128.42 billion, a PE ratio of 27.58, a PEG ratio of 2.42 and a beta of 0.77. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $102.59. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50.

    Medtronic (NYSE:MDTGet Free Report) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the previous year, the firm earned $1.26 EPS. Medtronic’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

    Medtronic Company Profile

    (Free Report)

    Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

    See Also

    Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDTFree Report).

    Institutional Ownership by Quarter for Medtronic (NYSE:MDT)



    Receive News & Ratings for Medtronic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medtronic and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Lake Street Capital Has Lowered Expectations for P3 Health Partners (NASDAQ:PIII) Stock Price

    [ad_1]

    P3 Health Partners (NASDAQ:PIIIGet Free Report) had its target price lowered by equities researchers at Lake Street Capital from $20.00 to $12.50 in a report issued on Monday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s target price points to a potential upside of 95.31% from the stock’s previous close.

    Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of P3 Health Partners in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $12.50.

    View Our Latest Stock Analysis on PIII

    P3 Health Partners Stock Up 7.0%

    PIII opened at $6.40 on Monday. The company has a debt-to-equity ratio of 2.29, a quick ratio of 0.31 and a current ratio of 0.32. The company has a market capitalization of $46.02 million, a PE ratio of -0.16 and a beta of 0.84. The stock’s fifty day moving average is $8.52 and its 200-day moving average is $7.64. P3 Health Partners has a one year low of $5.80 and a one year high of $14.50.

    P3 Health Partners (NASDAQ:PIIIGet Free Report) last released its earnings results on Friday, November 14th. The company reported ($9.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($8.70) by ($0.97). P3 Health Partners had a negative return on equity of 302.33% and a negative net margin of 9.07%.The firm had revenue of $345.25 million for the quarter, compared to analyst estimates of $346.64 million. P3 Health Partners has set its FY 2025 guidance at EPS. On average, equities analysts predict that P3 Health Partners will post -0.67 EPS for the current fiscal year.

    Institutional Trading of P3 Health Partners

    An institutional investor recently raised its position in P3 Health Partners stock. Trinity Financial Advisors LLC grew its holdings in P3 Health Partners Inc. (NASDAQ:PIIIFree Report) by 4.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,678 shares of the company’s stock after purchasing an additional 1,178 shares during the period. Trinity Financial Advisors LLC owned approximately 0.37% of P3 Health Partners worth $239,000 as of its most recent SEC filing. Institutional investors own 7.75% of the company’s stock.

    P3 Health Partners Company Profile

    (Get Free Report)

    P3 Health Partners Inc, a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc was founded in 2020 and is based in Henderson, Nevada.

    See Also



    Receive News & Ratings for P3 Health Partners Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for P3 Health Partners and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Allianz SE Decreases Stake in Johnson & Johnson $JNJ

    [ad_1]

    Allianz SE cut its position in Johnson & Johnson (NYSE:JNJFree Report) by 5.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 133,221 shares of the company’s stock after selling 8,085 shares during the period. Allianz SE’s holdings in Johnson & Johnson were worth $20,350,000 as of its most recent filing with the Securities and Exchange Commission.

    Several other institutional investors have also modified their holdings of the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $35,000. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson during the first quarter worth approximately $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson in the first quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. acquired a new stake in Johnson & Johnson during the first quarter worth approximately $65,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

    Johnson & Johnson Stock Performance

    Shares of JNJ opened at $194.52 on Thursday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $195.55. The stock has a market capitalization of $468.65 billion, a P/E ratio of 18.78, a P/E/G ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company’s fifty day moving average is $185.13 and its two-hundred day moving average is $169.48.

    Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

    Johnson & Johnson Announces Dividend

    The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

    Wall Street Analysts Forecast Growth

    JNJ has been the topic of a number of recent analyst reports. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a research report on Friday, October 10th. Argus set a $210.00 price objective on Johnson & Johnson in a report on Wednesday, October 15th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Finally, Stifel Nicolaus boosted their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $199.05.

    Check Out Our Latest Stock Report on Johnson & Johnson

    Insider Activity

    In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

    Johnson & Johnson Company Profile

    (Free Report)

    Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

    Featured Articles

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Arkadios Wealth Advisors Takes $300,000 Position in Edwards Lifesciences Corporation $EW

    [ad_1]

    Arkadios Wealth Advisors purchased a new stake in Edwards Lifesciences Corporation (NYSE:EWFree Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 3,840 shares of the medical research company’s stock, valued at approximately $300,000.

    Several other hedge funds have also modified their holdings of the business. Econ Financial Services Corp purchased a new position in Edwards Lifesciences during the second quarter worth $889,000. Pacific Capital Partners Ltd purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $1,760,000. Czech National Bank grew its position in shares of Edwards Lifesciences by 5.8% in the second quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after purchasing an additional 7,917 shares during the period. Mirova US LLC grew its position in shares of Edwards Lifesciences by 56.2% in the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after purchasing an additional 1,054,301 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Edwards Lifesciences by 111.9% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 163,202 shares of the medical research company’s stock valued at $12,532,000 after purchasing an additional 86,186 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

    Insider Activity at Edwards Lifesciences

    In other news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.29% of the company’s stock.

    Analysts Set New Price Targets

    A number of research analysts recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and issued a $95.00 target price (up previously from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Barclays restated an “overweight” rating and set a $99.00 price objective (up previously from $95.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Morgan Stanley boosted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Finally, Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

    View Our Latest Stock Report on Edwards Lifesciences

    Edwards Lifesciences Stock Performance

    EW opened at $82.86 on Thursday. The company has a market capitalization of $48.65 billion, a price-to-earnings ratio of 11.92, a price-to-earnings-growth ratio of 3.97 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a 1-year low of $64.89 and a 1-year high of $87.09. The business has a 50 day moving average price of $77.72 and a two-hundred day moving average price of $77.18.

    Edwards Lifesciences (NYSE:EWGet Free Report) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the firm earned $0.67 EPS. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

    Edwards Lifesciences Profile

    (Free Report)

    Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

    Featured Articles

    Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EWFree Report).

    Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)



    Receive News & Ratings for Edwards Lifesciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Edwards Lifesciences and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Sequoia Financial Advisors LLC Invests $233,000 in Royalty Pharma PLC $RPRX

    [ad_1]

    Sequoia Financial Advisors LLC purchased a new position in shares of Royalty Pharma PLC (NASDAQ:RPRXFree Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 6,470 shares of the biopharmaceutical company’s stock, valued at approximately $233,000.

    Several other large investors also recently modified their holdings of RPRX. Victory Capital Management Inc. increased its stake in shares of Royalty Pharma by 270.4% during the 1st quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company’s stock worth $112,788,000 after purchasing an additional 2,644,923 shares during the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Royalty Pharma by 2,543.7% during the 1st quarter. Los Angeles Capital Management LLC now owns 1,081,128 shares of the biopharmaceutical company’s stock worth $33,656,000 after purchasing an additional 1,040,234 shares during the last quarter. Jupiter Asset Management Ltd. increased its stake in shares of Royalty Pharma by 462.1% during the 1st quarter. Jupiter Asset Management Ltd. now owns 1,090,591 shares of the biopharmaceutical company’s stock worth $33,950,000 after purchasing an additional 896,555 shares during the last quarter. Nuveen LLC bought a new position in Royalty Pharma in the 1st quarter worth approximately $27,749,000. Finally, AQR Capital Management LLC boosted its holdings in Royalty Pharma by 37.0% in the 1st quarter. AQR Capital Management LLC now owns 2,608,090 shares of the biopharmaceutical company’s stock worth $80,381,000 after buying an additional 704,414 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

    Royalty Pharma Stock Up 0.0%

    Shares of NASDAQ:RPRX opened at $36.85 on Friday. The firm has a fifty day moving average price of $36.11 and a two-hundred day moving average price of $34.95. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26. Royalty Pharma PLC has a one year low of $24.05 and a one year high of $38.00. The company has a market cap of $21.49 billion, a price-to-earnings ratio of 21.30, a PEG ratio of 2.03 and a beta of 0.60.

    Royalty Pharma (NASDAQ:RPRXGet Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.10 by $0.04. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. The firm had revenue of $578.67 million during the quarter, compared to the consensus estimate of $750.06 million. Analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

    Royalty Pharma Announces Dividend

    The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Friday, November 14th. Royalty Pharma’s dividend payout ratio (DPR) is presently 50.87%.

    Analysts Set New Price Targets

    Several research firms recently commented on RPRX. Weiss Ratings raised shares of Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Citigroup raised their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, July 22nd. Morgan Stanley cut their price objective on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a report on Friday, October 10th. The Goldman Sachs Group began coverage on shares of Royalty Pharma in a report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Saturday, September 13th. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company. Based on data from MarketBeat.com, Royalty Pharma has an average rating of “Buy” and an average target price of $46.00.

    Get Our Latest Analysis on Royalty Pharma

    Royalty Pharma Company Profile

    (Free Report)

    Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

    Further Reading

    Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)



    Receive News & Ratings for Royalty Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Royalty Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link